Evidence map›Paper›PMID 32235930›Full record

Trial reportNature medicine2020

Effects of underfeeding and oral vancomycin on gut microbiome and nutrient absorption in humans.

Alessio Basolo, Maximilian Hohenadel, Qi Yan Ang, Paolo Piaggi, Sascha Heinitz, Mary Walter, Peter Walter, Shannon Parrington, Donovan D Trinidad, Reiner Jumpertz von Schwartzenberg and 2 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02037295 (Investigation of the Gut Microbiota in Regulating Nutrient Absorption in Humans), which is not on this map. Cited by 82 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 2 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02037295 phase2completednot on this map

Investigation of the Gut Microbiota in Regulating Nutrient Absorption in Humans

TypeinterventionalSponsorNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Ran2014 to 2019Enrolled27ConditionsObesityArmsVancomycin, Placebo oral tablet, Overfeeding diet (OF), Underfeeding diet (UF)
3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 2 syntheses or guidelines pooled it, 143 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Article
  13. Molecular evolution of animal aging.The EMBO journal · 2026
    Review
  14. Review
  15. Article
  16. Pharmacomicrobiomics.Clinical pharmacology and therapeutics · 2025
    Review
  17. Review
  18. Review
  19. Review
  20. Article

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Alessio Basolo *Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Phoenix, AZ, USA. alessio.basolo@nih.gov.ORCID http://orcid.org/0000-0001-9048-5248
Maximilian Hohenadel *Obesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Phoenix, AZ, USA.
Qi Yan Ang *Department of Microbiology and Immunology, University of California, San Francisco, CA, USA.
Paolo PiaggiObesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Phoenix, AZ, USA.
Sascha HeinitzObesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Phoenix, AZ, USA.
Mary WalterClinical Core Laboratory, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA.
Peter WalterClinical Mass Spectrometry Core, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD, USA.
Shannon ParringtonObesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Phoenix, AZ, USA.
Donovan D TrinidadDepartment of Microbiology and Immunology, University of California, San Francisco, CA, USA.
Reiner Jumpertz von SchwartzenbergDepartment of Endocrinology and Metabolic Diseases, Charité University Medicine, Berlin, Germany.
Peter J TurnbaughDepartment of Microbiology and Immunology, University of California, San Francisco, CA, USA. peter.turnbaugh@ucsf.edu.ORCID http://orcid.org/0000-0002-0888-2875
Jonathan KrakoffObesity and Diabetes Clinical Research Section, Phoenix Epidemiology and Clinical Research Branch National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Phoenix, AZ, USA. jkrakoff@mail.nih.gov.ORCID http://orcid.org/0000-0001-6074-5600
National Institutes of Health · USUniversity of California, San Francisco · USCharité - Universitätsmedizin Berlin · DENational Institute of Diabetes and Digestive and Kidney Diseases · US

Funding

Clinical Research and Assay SupportZICDK071006 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI WALTER, MARY · 2009 to 2025
$20.6M
UCSF Nutrition Obesity Research CenterP30DK098722 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHRISTIAN VAISSE · 2015 to 2026
$14.6M
Biobehavioral Studies of Obesity, Weight loss and RecidivismZIADK075007 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI MUNIYAPPA, RANGANATH · 2009 to 2025
$13.8M
Predicting and preventing drug metabolism by the human gut microbiomeR01HL122593 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Peter James Turnbaugh · 2016 to 2026
$5.7M
Nutrient Absorption in Lean Versus Obese IndividualsZIADK069089 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI KRAKOFF, JONATHAN · 2009 to 2020
$3.4M
(PQ10) Harnessing the human gut microbiome to predict chemotherapy outcomesR21CA227232 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ATREYA, CHLOE E., TURNBAUGH, PETER JAMES · 2018 to 2019
$378k
NCI NIH HHS R21 CA227232NHLBI NIH HHS R01 HL122593NIDDK NIH HHS P30 DK098722
6 · The paper itself

Abstract

Direct evidence in humans for the impact of the microbiome on nutrient absorption is lacking. We conducted an extended inpatient study using two interventions that we hypothesized would alter the gut microbiome and nutrient absorption. In each, stool calorie loss, a direct proxy of nutrient absorption, was measured. The first phase was a randomized cross-over dietary intervention in which all participants underwent in random order 3 d of over- and underfeeding. The second was a randomized, double-blind, placebo-controlled pharmacologic intervention using oral vancomycin or matching placebo (NCT02037295). Twenty-seven volunteers (17 men and 10 women, age 35.1 ± 7.3, BMI 32.3 ± 8.0), who were healthy other than having impaired glucose tolerance and obesity, were enrolled and 25 completed the entire trial. The primary endpoints were the effects of dietary and pharmacological intervention on stool calorie loss. We hypothesized that stool calories expressed as percentage of caloric intake would increase with underfeeding compared with overfeeding and increase during oral vancomycin treatment. Both primary endpoints were met. Greater stool calorie loss was observed during underfeeding relative to overfeeding and during vancomycin treatment compared with placebo. Key secondary endpoints were to evaluate the changes in gut microbial community structure as evidenced by amplicon sequencing and metagenomics. We observed only a modest perturbation of gut microbial community structure with under- versus overfeeding but a more widespread change in community structure with reduced diversity with oral vancomycin. Increase in Akkermansia muciniphila was common to both interventions that resulted in greater stool calorie loss. These results indicate that nutrient absorption is sensitive to environmental perturbations and support the translational relevance of preclinical models demonstrating a possible causal role for the gut microbiome in dietary energy harvest.

Indexed as

Administration, OralAdolescentAdultCaloric RestrictionCross-Over StudiesDietDouble-Blind MethodEnergy MetabolismFecesFemaleGastrointestinal MicrobiomeHumansIntestinal AbsorptionMaleMalnutritionMiddle AgedNutrientsVancomycin

Identifiers

PMID32235930
OpenAlexW3012563815

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.